GFM
BDTX icon

GF Fund Management’s Black Diamond Therapeutics BDTX Stock Holding History

GF Fund Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.71K Buy
1,272
+153
+14% +$364 ﹤0.01% 619
2025
Q4 		$2.72K Buy
+1,119
New +$3.96K ﹤0.01% 640

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GF Fund Management's BDTX Position: Q1 2026 in Review

GF Fund Management increased its Black Diamond Therapeutics (BDTX) stake by 14% in Q1 2026, buying an estimated $364 and bringing the position to 1,272 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #619.

GF Fund Management first reported a position in BDTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.72K in Q4 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • GF Fund Management held 1,272 shares of Black Diamond Therapeutics worth $2.71K as of Q1 2026.
  • GF Fund Management bought 153 Black Diamond Therapeutics shares in Q1 2026, an estimated $364.
  • Black Diamond Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #619 holding.
  • GF Fund Management first reported a position in Black Diamond Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • GF Fund Management's Black Diamond Therapeutics position peaked at $2.72K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.